Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 3/2015

01-09-2015 | Complications of Antiretroviral Therapy (JM Kilby, Section Editor)

The Role of Statins in the Setting of HIV Infection

Authors: Allison Ross Eckard, Grace A. McComsey

Published in: Current HIV/AIDS Reports | Issue 3/2015

Login to get access

Abstract

HIV-infected individuals are at an increased risk of cardiovascular disease (CVD) and other HIV-related co-morbidities. This is due in part to dyslipidemia associated with antiretroviral therapy and increased inflammation and immune activation from chronic HIV infection. Statins not only have potent lipid-lowering properties but are also anti-inflammatory and immunomodulators. Studies suggest that statin therapy in the HIV-infected population may decrease the risk of CVD and other non-AIDS-defining co-morbidities. This review summarizes the recent literature on statin use in the HIV setting.
Literature
1.
Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23:1841–9.PubMedCentralPubMedCrossRef
2.
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–12.PubMedCentralPubMedCrossRef
3.
Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5, e203.PubMedCentralPubMedCrossRef
4.
Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d’Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179–93.PubMedCrossRef
5.
Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2:517–26.PubMedCrossRef
6.
Tuomilehto J, Zimmet P, Mackay IR, Koskela P, Vidgren G, Toivanen L, et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet. 1994;343:1383–5.PubMedCrossRef
7.
Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRef
8.•
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–45. This report consists of updated recommendations for statin therapy use.PubMedCrossRef
9.
Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS. 2010;24:77–83.PubMedCrossRef
10.
Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr. 2005;39:307–12.PubMedCrossRef
11.
Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47:570–8.PubMedCrossRef
12.
Busti AJ, Bain AM, Hall 2nd RG, Bedimo RG, Leff RD, Meek C, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008;51:605–10.PubMedCrossRef
13.
14.
Calza L, Manfredi R, Colangeli V, Tampellini L, Sebastiani T, Pocaterra D, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS. 2005;19:1051–8.PubMedCrossRef
15.
Singh S, Willig JH, Mugavero MJ, Crane PK, Harrington RD, Knopp RH, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis. 2011;52:387–95.PubMedCentralPubMedCrossRef
16.
Hirsch M, O’Donnell JC, Jones P. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Eur J Cardiovasc Prev Rehabil. 2005;12:18–28.PubMed
17.
Strandberg TE, Feely J, Sigurdsson EL, Group Ds. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin Ther. 2004;26:1821–33.PubMedCrossRef
18.
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152–60.PubMedCrossRef
19.
Stender S, Schuster H, Barter P, Watkins C, Kallend D, Group MIS. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab. 2005;7:430–8.PubMedCrossRef
20.
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998,97:1440–1445.
21.
Stein JH, Merwood MA, Bellehumeur JL, Aeschlimann SE, Korcarz CE, Underbakke GL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J. 2004;147, E18.PubMed
22.
Hürlimann D, Chenevard R, Ruschitzka F, Flepp M, Enseleit F, Bechir M, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. Heart. 2006;92:110–2.PubMedCentralPubMedCrossRef
23.
Bonnet F, Balestre E, Thiebaut R, Mercie P, Dupon M, Morlat P, et al. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999–2001. HIV Med. 2004;5:133–9.PubMedCrossRef
24.
Bittar R, Giral P, Aslangul E, Assoumou L, Valantin MA, Kalmykova O, et al. Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor. AIDS. 2012;26:1801–5.PubMedCrossRef
25.•
Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209:1156–64. This randomized, placebo-controlled trial of rosuvastatin vs. placebo in ART-treated HIV-infected subjects showed that Lp-PLA 2 levels decreased with 24 weeks of statin use.
26.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.PubMedCrossRef
27.
Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179–84.PubMedCrossRef
28.
Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64.PubMedCrossRef
29.•
McComsey G, Jiang Y, Erlandson K, Debanne S. Rosuvastatin improves hip bone mineral density but worsens insulin resistance. Boston: Conference on retroviruses and opportunistic infections; 2014. This randomized, placebo-controlled trial of rosuvastatin vs. placebo in ART-treated HIV-infected subjects showed that insulin resistance may worsen with statin therapy in this population.
30.
Boccara F, Simon T, Lacombe K, Cohen A, Laloux B, Bozec E, et al. Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy. AIDS. 2006;20:2395–8.PubMedCrossRef
31.••
Longenecker C, Jiang Y, Debanne S, Labbato D, Kinley B, Storer N, et al. Rosuvastatin arrests progression of carotid intima-media thickness in treated HIV. Seattle: Conference on retroviruses and opportunistic infections; 2015. This randomized, placebo-controlled trial of rosuvastatin vs. placebo in ART-treated HIV-infected subjects showed that carotid IMT progression did not progress significantly with 96 weeks of statin therapy, although there was significant progression in the placebo group.
32.
Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–65.PubMedCrossRef
33.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–82.PubMedCrossRef
34.
35.
Ota H, Eto M, Kano MR, Kahyo T, Setou M, Ogawa S, et al. Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol. 2010;30:2205–11.PubMedCrossRef
36.
37.
Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M. Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol. 2010;159:1294–303.PubMedCentralPubMedCrossRef
38.
Amuro H, Ito T, Miyamoto R, Sugimoto H, Torii Y, Son Y, et al. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis Rheum. 2010;62:2073–85.PubMed
39.
Mira E, Manes S. Immunomodulatory and anti-inflammatory activities of statins. Endocr Metab Immune Disord Drug Targets. 2009;9:237–47.PubMedCrossRef
40.
Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4:977–87.PubMedCrossRef
41.
Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005;5:579–94.PubMedCentralPubMedCrossRef
42.
Yasuda H, Yuen PS, Hu X, Zhou H, Star RA. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int. 2006;69:1535–42.PubMedCentralPubMedCrossRef
43.
Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med. 2009;169:1658–67.PubMedCrossRef
44.
Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis. 2008;8:571–6.PubMedCrossRef
45.
Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sorensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med. 2008;168:2081–7.PubMedCrossRef
46.
Ross AC, Rizk N, O’Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2009;49:1119–27.PubMedCentralPubMedCrossRef
47.
Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268–73.PubMedCentralPubMedCrossRef
48.
Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859–70.PubMedCrossRef
49.
Aslangul E, Fellahi S, Assoumou LK, Bastard JP, Capeau J, Costagliola D. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS. 2011;25:1128–31.PubMedCrossRef
50.•
Calza L, Vanino E, Salvadori C, Manfredi R, Colangeli V, Cascavilla A, et al. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients. HIV Clin Trials. 2014;15:1–13. This study suggested that adding statin therapy at the time of ART initiation reduced inflammation more than ART alone.PubMedCrossRef
51.
Fichtenbaum CJ, Evans SE, Aberg JA. High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. AIDS. 2011;25:2053.PubMedCentralPubMedCrossRef
52.
De Wit S, Delforge M, Necsoi CV, Clumeck N. Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. AIDS. 2011;25:1332–3.PubMedCrossRef
53.
Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011;203:756–64.PubMedCentralPubMedCrossRef
54.•
Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis. 2014;58:588–95. This randomized, placebo-controlled trial of rosuvastatin vs. placebo in ART-treated HIV-infected subjects showed that monocyte activation decreased over 24 weeks with statin use.PubMedCentralPubMedCrossRef
55.•
Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;68:396–404. This randomized, placebo-controlled trial of rosuvastatin vs. placebo in ART-treated HIV-infected subjects showed that monocyte and lymphocyte activation and a number of inflammatory markers decreased over 48 weeks with statin use.PubMedCrossRef
56.
Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780–90.PubMedCentralPubMedCrossRef
57.
Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210:1248–59.PubMedCrossRef
58.
Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 2006;36:104–7.PubMedCrossRef
59.
Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010;33:375–86.PubMedCentralPubMedCrossRef
60.
Funderburg NT, Zidar DA, Shive C, Lioi A, Mudd J, Musselwhite LW, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood. 2012;120:4599–608.PubMedCentralPubMedCrossRef
61.
Lp PLASC, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536–44.CrossRef
62.
Investigators S, White HD, Held C, Stewart R, Tarka E, Brown R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370:1702–11.CrossRef
63.••
Rasmussen LD, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, Obel N. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS One. 2013;8:e52828. This cohort study showed that statin use significantly reduced all-cause mortality in HIV-infected patients who also had a co-morbidity diagnosis.PubMedCentralPubMedCrossRef
64.
Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One. 2011;6, e21843.PubMedCentralPubMedCrossRef
65.•
Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013;56:1471–9. This cohort study showed a significant reduction in non-AIDS-defining malignancies with statin use, but they also observed a significant increase in bacterial infections.PubMedCentralPubMedCrossRef
66.
Drechsler H, Zhang S, Maalouf N, Cutrell J, Tebas P, Bedimo R. Impact of statin exposure on mortality and non-AIDS complications in HIV patients on HAART. Atlanta: Conference on retroviruses and opportunistic infections; 2013.
67.
Chao C, Xu L, Abrams DI, Towner WJ, Horberg MA, Leyden WA, et al. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS. 2011;25:1771–7.PubMedCrossRef
68.
Corrales-Medina VF, Del Carpio F, Concha R, Symes S. Statins and HIV: beyond the metabolic and cardiovascular benefit. J Acquir Immune Defic Syndr. 2005;39:503–4.PubMedCrossRef
69.
Shimada K, Miyauchi K, Daida H. Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. Circulation. 2004;109:e213–4. author reply e213-214.PubMedCrossRef
70.
Narayan S, Hawley N, Giguere P, Badley AD. Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors. HIV Clin Trials. 2003;4:164–9.PubMedCrossRef
71.
Rodriguez B, Valdez H, Mijch A, Watson K, Lederman MM, McComsey GA, et al. Statins blunt HAART-induced CD4 T-cell gains but have no long-term effect on virologic response to HAART. J Int Assoc Physicians AIDS Care (Chic). 2007;6:198–202.CrossRef
72.
Negredo E, Clotet B, Puig J, Perez-Alvarez N, Ruiz L, Romeu J, et al. The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. AIDS. 2006;20:619–21.PubMedCrossRef
73.
Maziere JC, Landureau JC, Giral P, Auclair M, Fall L, Lachgar A, et al. Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium. Biomed Pharmacother. 1994;48:63–7.PubMedCrossRef
74.
Giguere JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol. 2004;78:12062–5.PubMedCentralPubMedCrossRef
75.
Moncunill G, Negredo E, Bosch L, Vilarrasa J, Witvrouw M, Llano A, et al. Evaluation of the anti-HIV activity of statins. AIDS. 2005;19:1697–700.PubMedCrossRef
76.
Amet T, Nonaka M, Dewan MZ, Saitoh Y, Qi X, Ichinose S, et al. Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect. 2008;10:471–80.PubMedCrossRef
77.
del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med. 2004;200:541–7.PubMedCentralPubMedCrossRef
Metadata
Title
The Role of Statins in the Setting of HIV Infection
Authors
Allison Ross Eckard
Grace A. McComsey
Publication date
01-09-2015
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 3/2015
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-015-0273-9

Other articles of this Issue 3/2015

Current HIV/AIDS Reports 3/2015 Go to the issue

Co-infections and Comorbidity (S Naggie, Section Editor)

Acute HCV in HIV-Infected MSM: Modes of Acquisition, Liver Fibrosis, and Treatment

Co-infections and Comorbidity (S Naggie, Section Editor)

Emerging Challenges in Managing Hepatitis B in HIV Patients

Co-infections and Comorbidity (S Naggie, Section Editor)

Drug Interactions of Hepatitis C Direct-Acting Antivirals in the HIV-Infected Person

Co-infections and Comorbidity (S Naggie, Section Editor)

Treatment of Chronic HCV Genotype 1 Coinfection

Co-infections and Comorbidity (S Naggie, Section Editor)

The Role of Viral Co-Infection in HIV-Associated Non-AIDS-Related Cancers

Co-infections and Comorbidity (S Naggie, Section Editor)

Extrahepatic Manifestations of Hepatitis C Infection: Navigating CHASM
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits